Streetbeat News

Analyst Ratings

BKNG

Wedbush analyst Scott Devitt has reiterated an Outperform rating on Booking Holdings (NASDAQ:BKNG) and maintained a price target of $3850 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 5:11 pm

HXL

UBS analyst Gavin Parsons downgraded Hexcel (NYSE:HXL) from Buy to Neutral and reduced the price target from $87 to $72.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 5:07 pm

UPWK

JMP Securities analyst Andrew Boone has reiterated a 'Market Outperform' rating on Upwork (NASDAQ:UPWK) and maintained a price target of $16. This reaffirmation of Upwork's stock performance and price target suggests continued confidence in the company's potential for growth and market performance.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 5:01 pm

ZG

Over the past three months, 8 analysts have provided diverse opinions on Zillow Group (NASDAQ:ZG), with ratings ranging from bullish to indifferent. The average 12-month price target is $55.75, with a high of $66.00 and a low of $36.00, marking a 5.11% decrease in the average target. Analysts from firms like RBC Capital, Benchmark, JMP Securities, Deutsche Bank, Susquehanna, and Piper Sandler have adjusted their ratings and price targets, reflecting their latest views on the company's performance. Zillow Group operates in real estate and has shown a revenue growth rate of 2.69% as of September 30, 2023, but struggles with a net margin of -5.65%. The company's ROE and ROA outperform industry averages, and it maintains a healthy debt-to-equity ratio of 0.42.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 5:01 pm

GH

Guardant Health (NASDAQ:GH) received mixed analyst ratings in the latest quarter, with 2 bullish and 2 somewhat bullish ratings. The average 12-month price target is now $37.75, down from $47.00. Analysts from Goldman Sachs, Raymond James, and Morgan Stanley adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Guardant Health is known for its liquid-based cancer tests and has shown a revenue growth rate of 21.83% as of September 30, 2023. However, the company faces challenges with a net margin of -60.2%, ROE of -33.05%, ROA of -4.73%, and a high debt-to-equity ratio of 5.95.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 5:01 pm

SBCF

Seacoast Banking (NASDAQ:SBCF) has received mixed analyst ratings over the last quarter, with a shift towards a more bullish sentiment in the last 30 days. The average 12-month price target for SBCF is now $29.38, up from $25.00, with a high estimate of $33.00 and a low of $27.50. Analysts from Truist Securities and Raymond James have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Seacoast Banking's financials show challenges in revenue growth, net margin, ROE, and ROA, but a positive aspect in its low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 5:00 pm

SRPT

Sarepta Therapeutics (NASDAQ:SRPT) has been rated by 12 financial analysts over the past three months, with sentiments ranging from bullish to bearish. The average 12-month price target is $148.92, up 32.26% from the previous $112.60, with a high estimate of $224.00 and a low of $80.00. Analysts have maintained, raised, or lowered their ratings and price targets in response to market conditions and company performance. Sarepta is a biotech company focusing on rare diseases, with a recent revenue growth of 44.1% but with a net margin of -12.34% and an ROE of -5.44%. The company's debt-to-equity ratio is 1.79, higher than the industry average.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 5:00 pm

WWD

Truist Securities has maintained a Hold rating on Woodward (NASDAQ:WWD) but increased its price target from $136.00 to $143.00. Woodward's shares are currently trading at $151.00, up 5.8% over the last 24 hours. The new price target suggests a potential downside of 5.3% from the current share price. Woodward is a provider of control solutions for the aerospace and industrial markets, with facilities in the US, Europe, and Asia.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 5:00 pm

ENFN

JP Morgan has downgraded Enfusion (NYSE:ENFN) to Underweight with a new price target of $9.00, down from $11.00. Enfusion's shares are currently trading at $8.19, down 3.65% over the last 24 hours. The new price target suggests a potential upside of 9.89% from the current share price. Enfusion is a SaaS provider aiming to transform the investment management industry by unifying systems and data.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 5:00 pm

STR

Analysts have recently updated their ratings and price targets for Sitio Royalties (NYSE:STR), with 4 analysts offering a range of bullish to somewhat bullish opinions. The average 12-month price target is now $28.75, down from the previous $32.33, indicating a potential decrease in stock value. Analysts from Truist Securities, Piper Sandler, Stifel, and Keybanc have adjusted their price targets and ratings, reflecting their current views on the company's performance and market conditions. Sitio Royalties, a mineral and royalty company, has shown a revenue growth rate of 35.68% as of September 30, 2023, but has below-average net margin and ROE, indicating profitability challenges.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 5:00 pm